Carl  LeBel net worth and biography

Carl LeBel Biography and Net Worth

Carl has been the Chief Development Officer at Frequency since 2018. He started LeBel Consulting LLC after serving as the Chief Scientific Officer at Otonomy, Inc., from 2009 to 2016. Before joining Otonomy, he was President and CEO of Akesis Pharmaceuticals, Inc., a virtual metabolic disorders company, and prior to that spent more than 14 years at Amgen as an executive director in a variety of R&D management positions. Carl also worked as a research scientist at Alkermes Inc. and started his career as a consultant at Arthur D. Little, a management and technology consulting firm where he worked across several industries.

Carl is a scientific fellow of the American Academy of Otolaryngology, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. He received his B.S. in Chemistry from the University of Detroit and his Ph.D. in Biomedical Sciences/Toxicology from Northeastern University. He was a NIEHS post-doctoral fellow in Molecular Neurotoxicology at the University of California Irvine. Carl is also a co-inventor on numerous patents in the field of drug delivery for otology-related disorders.

What is Carl LeBel's net worth?

The estimated net worth of Carl LeBel is at least $3,895.10 as of November 21st, 2016. Dr. LeBel owns 13,001 shares of Frequency Therapeutics stock worth more than $3,895 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. LeBel may own. Learn More about Carl LeBel's net worth.

How do I contact Carl LeBel?

The corporate mailing address for Dr. LeBel and other Frequency Therapeutics executives is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. Frequency Therapeutics can also be reached via phone at 781-315-4600 and via email at [email protected]. Learn More on Carl LeBel's contact information.

Has Carl LeBel been buying or selling shares of Frequency Therapeutics?

Carl LeBel has not been actively trading shares of Frequency Therapeutics within the last three months. Most recently, Carl Lebel sold 844 shares of the business's stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $4.33, for a transaction totalling $3,654.52. Learn More on Carl LeBel's trading history.

Who are Frequency Therapeutics' active insiders?

Frequency Therapeutics' insider roster includes Carl LeBel (Insider), Christopher Loose (Insider), Quentin McCubbin (Insider), and Peter Pfreundschuh (CFO). Learn More on Frequency Therapeutics' active insiders.

Are insiders buying or selling shares of Frequency Therapeutics?

During the last twelve months, insiders at the sold shares 46 times. They sold a total of 65,319 shares worth more than $36,102.94. The most recent insider tranaction occured on August, 18th when VP Richard J Mitrano sold 227 shares worth more than $143.01. Insiders at Frequency Therapeutics own 16.8% of the company. Learn More about insider trades at Frequency Therapeutics.

Information on this page was last updated on 8/18/2023.

Carl LeBel Insider Trading History at Frequency Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2022Sell844$4.33$3,654.52View SEC Filing Icon  
See Full Table

Carl LeBel Buying and Selling Activity at Frequency Therapeutics

This chart shows Carl Lebel's buying and selling at Frequency Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Frequency Therapeutics Company Overview

Frequency Therapeutics logo
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $0.30
Low: $0.28
High: $0.32

50 Day Range

MA: $0.58
Low: $0.22
High: $14.98

2 Week Range

Now: $0.30
Low: $0.18
High: $16.00

Volume

309,164 shs

Average Volume

822,537 shs

Market Capitalization

$10.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84